Annovis Bio Raises $15 Million in Public Offering to Fund Neurodegenerative Disease Trials
Annovis Bio has priced a $15 million public offering of common stock and warrants, with proceeds earmarked for clinical development of its lead candidate buntanetap for Alzheimer's and Parkinson's diseases.
Annovis Bio Inc. (NYSE: ANVS), a clinical-stage biotechnology company focused on neurodegenerative diseases, announced the pricing of an underwritten public offering of 7,895,000 shares of common stock and accompanying warrants to purchase up to 7,105,500 additional shares at a combined offering price of $1.90 per share and warrant. The company expects gross proceeds of approximately $15 million before expenses, with net proceeds intended to support continued clinical development of buntanetap for Alzheimer's and Parkinson's disease, as well as working capital and general corporate purposes.
The offering underscores Annovis's commitment to advancing its lead drug candidate, buntanetap (formerly posiphen), an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, the company aims to halt disease progression and improve cognitive and motor functions in patients. The additional funding comes at a critical time as Annovis progresses through Phase 3 clinical trials for both Alzheimer's and Parkinson's diseases.
This capital raise is significant for the biotechnology sector as it demonstrates continued investor interest in therapies targeting neurodegenerative conditions, which affect millions worldwide. Alzheimer's disease alone is a leading cause of dementia, while Parkinson's disease impacts motor function and quality of life. Annovis's approach of targeting multiple neurotoxic proteins could potentially offer a more comprehensive treatment option compared to existing therapies that focus on single pathways.
The offering structure, combining common stock and warrants, allows Annovis to secure funding while providing investors with potential upside through warrant exercises. The company is headquartered in Malvern, Pennsylvania, and is listed on the New York Stock Exchange under the ticker ANVS. For more information, visit the company's website at www.annovisbio.com.
The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS. The full press release detailing the offering can be accessed at https://ibn.fm/KRpCW.